Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience | Synapse
March 28, 2026Open Access
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience
Key Points
To evaluate the outcomes of a combination therapy in treating multiple myeloma that is refractory to lenalidomide and anti-CD38 monoclonal antibodies.
Real-world experience analysis of treatment outcomes
Combination therapy of pomalidomide, bortezomib, and dexamethasone
Assessment of patient response and side effects
Improvement in patient response rates observed
Potential survival benefits noted
Side effects consistent with known profiles of the drugs used